Peptides DB

Research-centric peptide and protocol reference hub

MK-677 (Ibutamoren)

Research-centric overview

Share
Peptide

Summary not yet generated. The Librarian will pick this up on the next daily run (12:00 UTC).

Community effect votes, structured logs, and side-effect summaries.

Effect profile (overview)

Aggregate AI baseline blended with community voting. Hover to inspect effect strengths per category.

Effect profile (AI + community): Muscle & body comp 4.0/5 · Metabolic & appetite 3.0/5 · Sleep & circadian 2.0/5Healing 0.0Muscle 4.0Metabolic 3.0Neuro 0.0Sleep 2.0Inflammation 0.0Skin 0.0

Effect scores blend an AI baseline with community votes. Open the full chart to see sliders and vote on each category.

Research log summary heatmap

Compact view of how logs describe shifts in pain, sleep, and performance (−5 to +5). Treat this as qualitative, anonymous signal only.

No community research logs yet. When structured logs are added, this panel will summarize typical shifts in pain, sleep, and performance.

Anonymous side-effect patterns

Rough heatmap of anonymous side-effect and positive-signal tags — a "most-mentioned" snapshot, not safety or efficacy advice.

No anonymous side-effect reports yet. When reports are submitted, this panel will show a simple heatmap of tags like "nausea", "flushing", "improved healing", and more.

Research footprint

Last analyzed Apr 17, 2026
4
Studies indexed
0
Human
1
Animal
3
AI analyzed
Evidence mix0% human · 25% animal · 0% cellular · 0% review
Highest phase: Preclinical onlyYears covered: 2023

Research & intelligence feed

Studies, clinical trials, community discussions, and news.

A Multicenter, 12-Month, Randomized, Double Blind, Placebo-Controlled Phase 3 Efficacy and Safety Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children With Growth Hormone Deficiency (GHD)Clinical TrialClinicalTrials.govApr 16, 2026

This study evaluated the efficacy and safety of daily oral LUM-201 in prepubertal children with growth hormone deficiency (GHD). The study was randomized, double-blind, and placebo-controlled, spanning 12 months. No therapeutic claims are made regarding the outcomes.

Phase: PHASE3Status: RECRUITING
The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease: A Pilot StudyClinical TrialClinicalTrials.govApr 16, 2026

This pilot study evaluated the impact of Ibutamoren on nonalcoholic fatty liver disease (NAFLD). The study's population, dosage, and specific outcomes are not detailed in the abstract. No therapeutic claims are made.

Phase: PHASE2Status: COMPLETED
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's DiseaseClinical TrialClinicalTrials.govApr 16, 2026

This study evaluated the safety and efficacy of MK-0677 (25 mg) in slowing the progression of Alzheimer's disease. The trial was randomized, double-blind, and placebo-controlled. Not reported in abstract.

Phase: PHASE2Status: COMPLETED
A Phase 2, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Determine Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Subjects With Stage 4 and Stage 5 Kidney DiseaseClinical TrialClinicalTrials.govApr 16, 2026

This study investigated the effects of MK-677 on lean body mass in subjects with chronic kidney disease (CKD) stages 4 and 5. The study was a phase 2, randomized, double-blind, placebo-controlled trial. Not reported in abstract.

Phase: PHASE2Status: WITHDRAWN
Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older AdultsClinical TrialClinicalTrials.govApr 16, 2026

This study evaluated the effects of MK-677, an oral GH secretagogue, on body composition and functional ability in older adults. The specific doses and outcomes measured were not detailed in the abstract. The findings suggest potential changes in body composition and function, but no therapeutic claims are made.

Phase: PHASE1, PHASE2Status: COMPLETED
Semantic Scholar search for MK-677 (Ibutamoren)StudySemanticScholarDec 12, 2025
LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report.StudyPubMedDec 12, 2025

Not reported in abstract.

Detection of the growth hormone secretagogue MK-0677 in equine hair following oral administration.StudyPubMedDec 12, 2025

MK-677 was detected in equine hair at concentrations of 0.5 to 2.5 ng/mg after oral administration, but the clinical implications of these findings are not established.

Knowing the minimal detectable dose can facilitate the interpretation of a hair test result: II. Case example with ibutamoren (MK-677), a growth hormone secretagogue.StudyPubMedDec 12, 2025

Not reported in abstract.

External databases

Helpful external resources for additional structural, pharmacologic, and literature context. These are third-party databases; always cross-check details with primary research.

Community notes

No comments yet. Share research notes, citations, or observations below.

Comments appear immediately.

Community research logs (detail)

No community research logs yet. Use the “Contribute data” button above to share an anonymized summary of your experience.

Anonymous side-effect reporting (detail)

This section describes how anonymous side-effect reports are aggregated into the heatmap above. Reports are anonymous and unverified, and should be read alongside primary safety data.

Use the "Report side effects" button to open a focused popup form. Please keep descriptions neutral and avoid medical language; think in terms of "nausea", "flushing", "vivid dreams", etc.